Neuroprotective properties of 17β-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice

Synapse

Volumn 41, Issue 2, 2001, Pages 131-138

  Callier, Sophie ^a,b   Morissette, Marc ^a   Grandbois, Michelle ^a   Pélaprat, Didier ^b   Di Paolo, Thérèse ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

Dopamine transporter; Glutamate; Selective estrogen receptor modulator; Steroid

Indexed keywords

AMPA RECEPTOR; CARRIER PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; ESTRADIOL; MEMBRANE PROTEIN; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE PROTEIN; NEUROPROTECTIVE AGENT; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SLC6A3 PROTEIN, MOUSE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLUTAMATE RECEPTOR;

ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; GENETICS; MALE; METABOLISM; MOUSE; NEOSTRIATUM; NERVE CELL; NERVE TRACT; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOASSAY; SUBSTANTIA NIGRA; ANIMAL EXPERIMENT; ANIMAL TISSUE; BRAIN PROTECTION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; NERVE CELL LESION; NERVE ENDING; NEUROTOXICITY; NONHUMAN; PERIKARYON; PRIORITY JOURNAL; STEREOSPECIFICITY; TISSUE LEVEL;

ANIMALS; CARRIER PROTEINS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; ESTRADIOL; GENE EXPRESSION; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEURAL PATHWAYS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PROGESTERONE; RADIOLIGAND ASSAY; RALOXIFENE; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SUBSTANTIA NIGRA;

EID: 0034743548     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.1067     Document Type: Article

References (62)

1. Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters
2. 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro
3. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship
4. Estrogenic stimulation of neurite growth in midbrain dopaminergic neurons depends on cAMP/protein kinase A signaling
5. Raloxifene (LY139481-HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
6. Riluzole and experimental parkinsonism: Antagonism of MPTP induced decrease in central dopamine levels in mice
7. Riluzole and experimental parkinsonism: Partial antagonism of MPP(+)-induced increase in striatal extracellular dopamine in rats in vivo
8. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice
9. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
10. Dendrite loss is a characteristic early indicator of toxin-induced neurodegeneration in rat midbrain slices
11. Stereospecific prevention by 17β-estradiol of MPTP-induced dopamine depletion in mice
12. Effects of a chronic lithium treatment on central dopamine neurotransporters
13. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
14. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo
15. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
16. +, a metabolite of MPTP, by brain synaptosomes
17. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement
18. Regional and selective effects of oestradiol and progesterone on NMDA and AMPA receptors in the rat brain
19. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures
20. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
21. An examination of male-female differences in progression and mortality of Parkinson's disease
22. Inhibition of striatal dopamine transporter activity by 17β-estradiol
23. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/Bl mice
24. Drug treatment of Parkinson's disease. Time for phase II
25. Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter
26. Ovarian steroid and raloxifene prevent MPTP-induced dopamine depletion in mice
27. 17α-estradiol exerts neuroprotective effects on SK-N-SH cells
28. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice
29. Phosphatidylinositol 3-kinase mediates neuroprotection by estrogen in cultured cortical neurons
30. Molecular mechanism of monoamine toxicity in Parkinson's disease: Hypothetical cell death model
31. Mechanism of action and cross-talk between estrogen receptor and progesterone receptor pathways
32. Ovarian hormones influence the morphology, distribution, and density of tyrosine hydroxylase immunoreactive axons in the dorsolateral prefrontal cortex of adult rhesus monkeys
33. Expression of aromatase in the embryonic and postnatal mouse striatum
34. Expression of estrogen receptor-alpha and beta mRNA in the developing and adult mouse striatum
35. Parkinson death rates by race, sex and geography
36. Expression and neuropeptidergic characterization of estrogen receptors (ERα and ERβ) throughout the rat brain: Anatomical evidence of distinct roles of each subtype
37. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration
38. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
39. Selective nigral toxicity after systemic administration of 1-methyl 4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) in the squirrel monkey
40. Rate of cell death in parkinsonism indicates active neuropathological processes
41. The impact of gender and estrogen on striatal dopaminergic neurotoxicity
42. Dopamine transporters and neuronal injury
43. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites
44. Sex and estrous cycle variations on rat striatal dopamine uptake sites
45. Effect of estradiol and progesterone on rat striatal uptake sites
46. Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells
47. Ontogeny of aromatase messenger ribonucleic acid and aromatase activity in the rat midbrain
48. Comparative study of voltage sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents
49. Sex steroids promote neurite growth in mesencephalic tyrosine hydroxylase immunoreactive neurons in vitro
50. Brain dopamine transporter: Gender differences and effect of chronic haloperidol
51. Gender differences in acute CNS trauma and stroke: Neuroprotective effects of estrogen and progesterone
52. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
53. The effect of estrogen replacement on early Parkinson's disease
54. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death
55. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons
56. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
57. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations
58. + neurotoxicity by N-methyl D-aspartate antagonists
59. 17β-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors
60. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats
61. Glutamate receptor binding sites in MPTP-treated mice